Evidence map›Paper›PMID 33145157›Full record

ArticleRespiratory medicine case reports2020

Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer.

Chrysanthi Sardeli, Paul Zarogoulidis, Konstantinos Romanidis, Panagoula Oikonomou, Konstantinos Sapalidis, Haidong Huang, Chong Bai, Wolfgang Hohenforst-Schmidt, Kosmas Tsakiridis, Bojan Zaric and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chrysanthi SardeliDepartment of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Paul ZarogoulidisDepartment of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Konstantinos RomanidisSecond Department of Surgery, University Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Panagoula OikonomouSecond Department of Surgery, University Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Konstantinos Sapalidis3rd Department of Surgery, ''AHEPA'' University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
Haidong HuangDepartment of Respiratory & Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China.
Chong BaiDepartment of Respiratory & Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China.
Wolfgang Hohenforst-SchmidtSana Clinic Group Franken, Department of Cardiology / Pulmonology / Intensive Care / Nephrology, ''Hof'' Clinics, University of Erlangen, Hof, Germany.
Kosmas TsakiridisThoracic Surgery Department, ''Interbalkan'' European Medical Center, Thessaloniki, Greece.
Bojan ZaricInstitute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia.
Branislav PerinInstitute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia.
Aris IoannidisSurgery Department, ''Genesis'' Private Hospital, Thessaloniki, Greece.
Sofia BakaOncology Department, ''Intebalkan'' European Medical Center, Thessaloniki, Greece.
Konstantinos DrevelegasRadiology Department, ''Euromedica'' Private Radiology Laboratory, Thessaloniki, Greece.
Maria KosmidouInternal Medicine, University Hospital of Ioannina, Ioannina, Greece.
Christoforos Kosmidis3rd Department of Surgery, ''AHEPA'' University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nowadays we have novel therapies for advanced stage non-small cell lung cancer. Immunotherapy has been introduced in the market for several years and until now its administration is mostly based on the programmed death-ligand 1. First line treatment with immunotherapy can be administered alone if programmed death-ligand 1 expression is ≥ 50%. All therapies for advanced stage disease have advantages and disadvantages, immunotherapy until now has presented mild adverse effects when compared to chemotherapy. However; it is known to induce inflammatory response to different tissues within the body. In our case acute pneumothorax was induced after immunotherapy administration.

Indexed as

EBUSImmunotherapyNon-small cell lung cancerPembrolizumabPneumothorax

Identifiers

PMID33145157
PMCPMC7596337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.